{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T07:40:16Z","timestamp":1790840416036,"version":"4.1.0"},"reference-count":144,"publisher":"MDPI AG","issue":"22","license":[{"start":{"date-parts":[[2020,11,18]],"date-time":"2020-11-18T00:00:00Z","timestamp":1605657600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009863","name":"Neuroendocrine Tumor Research Foundation","doi-asserted-by":"publisher","award":["653132"],"award-info":[{"award-number":["653132"]}],"id":[{"id":"10.13039\/100009863","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Despite significant advances made in cancer treatment, the development of therapeutic resistance to anticancer drugs represents a major clinical problem that limits treatment efficacy for cancer patients. Herein, we focus on the response and resistance to current antiangiogenic drugs and immunotherapies and describe potential strategies for improved treatment outcomes. Antiangiogenic treatments that mainly target vascular endothelial growth factor (VEGF) signaling have shown efficacy in many types of cancer. However, drug resistance, characterized by disease recurrence, has limited therapeutic success and thus increased our urgency to better understand the mechanism of resistance to inhibitors of VEGF signaling. Moreover, cancer immunotherapies including immune checkpoint inhibitors (ICIs), which stimulate antitumor immunity, have also demonstrated a remarkable clinical benefit in the treatment of many aggressive malignancies. Nevertheless, the emergence of resistance to immunotherapies associated with an immunosuppressive tumor microenvironment has restricted therapeutic response, necessitating the development of better therapeutic strategies to increase treatment efficacy in patients. Angiopoietin-2 (ANG2), which binds to the receptor tyrosine kinase TIE2 in endothelial cells, is a cooperative driver of angiogenesis and vascular destabilization along with VEGF. It has been suggested in multiple preclinical studies that ANG2-mediated vascular changes contribute to the development and persistence of resistance to anti-VEGF therapy. Further, emerging evidence suggests a fundamental link between vascular abnormalities and tumor immune evasion, supporting the rationale for combination strategies of immunotherapy with antiangiogenic drugs. In this review, we discuss the recent mechanistic and clinical advances in targeting angiopoietin signaling, focusing on ANG2 inhibition, to enhance therapeutic efficacy of antiangiogenic and ICI therapies. In short, we propose that a better mechanistic understanding of ANG2-mediated vascular changes will provide insight into the significance of ANG2 in treatment response and resistance to current antiangiogenic and ICI therapies. These advances will ultimately improve therapeutic modalities for cancer treatment.<\/jats:p>","DOI":"10.3390\/ijms21228689","type":"journal-article","created":{"date-parts":[[2020,11,18]],"date-time":"2020-11-18T07:41:00Z","timestamp":1605685260000},"page":"8689","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":89,"title":["The Angiopoietin-2 and TIE Pathway as a Therapeutic Target for Enhancing Antiangiogenic Therapy and Immunotherapy in Patients with Advanced Cancer"],"prefix":"10.3390","volume":"21","author":[{"given":"Alessandra","family":"Leong","sequence":"first","affiliation":[{"name":"Department of Pathology and Cell Biology, Columbia University Irving Medical Center, New York, NY 10032, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minah","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Pathology and Cell Biology, Columbia University Irving Medical Center, New York, NY 10032, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,11,18]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1038\/74651","article-title":"Mechanisms of angiogenesis and arteriogenesis","volume":"6","author":"Carmeliet","year":"2000","journal-title":"Nat. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/S0092-8674(00)80108-7","article-title":"Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis","volume":"86","author":"Hanahan","year":"1996","journal-title":"Cell"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1200\/JCO.2012.46.3653","article-title":"Normalizing tumor microenvironment to treat cancer: Bench to bedside to biomarkers","volume":"31","author":"Jain","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.ccell.2014.10.006","article-title":"Antiangiogenesis strategies revisited: From starving tumors to alleviating hypoxia","volume":"26","author":"Jain","year":"2014","journal-title":"Cancer Cell"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.ccr.2005.09.005","article-title":"Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors","volume":"8","author":"Casanovas","year":"2005","journal-title":"Cancer Cell"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"3584","DOI":"10.1200\/JCO.2008.20.1293","article-title":"Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma","volume":"27","author":"Motzer","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.ccr.2009.01.027","article-title":"Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis","volume":"15","author":"Allen","year":"2009","journal-title":"Cancer Cell"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/nrclinonc.2018.29","article-title":"Enhancing cancer immunotherapy using antiangiogenics: Opportunities and challenges","volume":"15","author":"Fukumura","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2943","DOI":"10.1158\/0008-5472.CAN-12-4354","article-title":"Vascular normalization as an emerging strategy to enhance cancer immunotherapy","volume":"73","author":"Huang","year":"2013","journal-title":"Cancer Res."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/nrm2639","article-title":"Control of vascular morphogenesis and homeostasis through the angiopoietin-Tie system","volume":"10","author":"Augustin","year":"2009","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1073\/pnas.96.5.1904","article-title":"Angiopoietins 3 and 4: Diverging gene counterparts in mice and humans","volume":"96","author":"Valenzuela","year":"1999","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1038\/35025215","article-title":"Vascular-specific growth factors and blood vessel formation","volume":"407","author":"Yancopoulos","year":"2000","journal-title":"Nature"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Griffin, M.E., Sorum, A.W., Miller, G.M., Goddard, W.A., and Hsieh-Wilson, L.C. (2020). Sulfated glycans engage the Ang-Tie pathway to regulate vascular development. Nat. Chem. Biol.","DOI":"10.1038\/s41589-020-00657-7"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1016\/j.cell.2019.07.021","article-title":"LECT2, a Ligand for Tie1, Plays a Crucial Role in Liver Fibrogenesis","volume":"178","author":"Xu","year":"2019","journal-title":"Cell"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1038\/ncb1715","article-title":"Angiopoietins assemble distinct Tie2 signalling complexes in endothelial cell-cell and cell-matrix contacts","volume":"10","author":"Saharinen","year":"2008","journal-title":"Nat. Cell Biol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1083\/jcb.200411105","article-title":"Multiple angiopoietin recombinant proteins activate the Tie1 receptor tyrosine kinase and promote its interaction with Tie","volume":"169","author":"Saharinen","year":"2005","journal-title":"J. Cell Biol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.molcel.2010.02.007","article-title":"Tie1-Tie2 interactions mediate functional differences between angiopoietin ligands","volume":"37","author":"Seegar","year":"2010","journal-title":"Mol. Cell"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/376070a0","article-title":"Distinct roles of the receptor tyrosine kinases Tie-1 and Tie- 2 in blood vessel formation","volume":"376","author":"Sato","year":"1995","journal-title":"Nature"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1016\/S0092-8674(00)81813-9","article-title":"Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis","volume":"87","author":"Suri","year":"1996","journal-title":"Cell"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1101\/gad.8.16.1897","article-title":"Dominant-negative and targeted null mutations in the endothelial receptor tyrosine kinase, tek, reveal a critical role in vasculogenesis of the embryo","volume":"8","author":"Dumont","year":"1994","journal-title":"Genes Dev."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/S0092-8674(00)80595-4","article-title":"Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor","volume":"96","author":"Brunet","year":"1999","journal-title":"Cell"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1016\/S0092-8674(00)81812-7","article-title":"Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning","volume":"87","author":"Davis","year":"1996","journal-title":"Cell"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1101\/gad.1189704","article-title":"Angiopoietin-1 modulates endothelial cell function and gene expression via the transcription factor FKHR (FOXO1)","volume":"18","author":"Daly","year":"2004","journal-title":"Genes Dev."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1161\/01.RES.86.1.24","article-title":"Angiopoietin-1 regulates endothelial cell survival through the phosphatidylinositol 3\u2032-Kinase\/Akt signal transduction pathway","volume":"86","author":"Kim","year":"2000","journal-title":"Circ. Res."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"45276","DOI":"10.1074\/jbc.M208063200","article-title":"Phosphorylation of serine 256 suppresses transactivation by FKHR (FOXO1) by multiple mechanisms. Direct and indirect effects on nuclear\/cytoplasmic shuttling and DNA binding","volume":"277","author":"Zhang","year":"2002","journal-title":"J. Biol. Chem."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1172\/JCI23126","article-title":"Involvement of Foxo transcription factors in angiogenesis and postnatal neovascularization","volume":"115","author":"Potente","year":"2005","journal-title":"J. Clin. Investig."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/S1534-5807(02)00217-4","article-title":"Angiopoietin-2 is required for postnatal angiogenesis and lymphatic patterning, and only the latter role is rescued by angiopoietin-1","volume":"3","author":"Gale","year":"2002","journal-title":"Dev. Cell"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s00441-006-0360-8","article-title":"Abnormal recruitment of periendothelial cells to lymphatic capillaries in digestive organs of angiopoietin-2-deficient mice","volume":"328","author":"Shimoda","year":"2007","journal-title":"Cell Tissue Res."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.ydbio.2008.04.024","article-title":"Defective remodeling and maturation of the lymphatic vasculature in Angiopoietin-2 deficient mice","volume":"319","author":"Dellinger","year":"2008","journal-title":"Dev. Biol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"eaax8013","DOI":"10.1126\/scitranslmed.aax8013","article-title":"Characterization of ANGPT2 mutations associated with primary lymphedema","volume":"12","author":"Leppanen","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1016\/S0002-9440(10)63242-7","article-title":"Dysmorphogenesis of kidney cortical peritubular capillaries in angiopoietin-2-deficient mice","volume":"165","author":"Pitera","year":"2004","journal-title":"Am. J. Pathol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1002\/jcp.10128","article-title":"Angiopoietin-2 plays an important role in retinal angiogenesis","volume":"192","author":"Hackett","year":"2002","journal-title":"J. Cell Physiol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"4150","DOI":"10.1182\/blood-2003-10-3685","article-title":"The Tie-2 ligand angiopoietin-2 is stored in and rapidly released upon stimulation from endothelial cell Weibel-Paladebodies","volume":"103","author":"Fiedler","year":"2004","journal-title":"Blood"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"3511","DOI":"10.1172\/JCI84871","article-title":"Opposing actions of angiopoietin-2 on Tie2 signaling and FOXO1 activation","volume":"126","author":"Kim","year":"2016","journal-title":"J. Clin. Investig."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"15491","DOI":"10.1073\/pnas.0607538103","article-title":"Angiopoietin-2 functions as an autocrine protective factor in stressed endothelial cells","volume":"103","author":"Daly","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1128\/MCB.01472-08","article-title":"Angiopoietin 2 is a partial agonist\/antagonist of Tie2 signaling in the endothelium","volume":"29","author":"Yuan","year":"2009","journal-title":"Mol. Cell Biol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1096\/fj.03-1466com","article-title":"Biological characterization of angiopoietin-3 and angiopoietin-4","volume":"18","author":"Lee","year":"2004","journal-title":"FASEB J."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"6119","DOI":"10.1158\/0008-5472.CAN-04-1054","article-title":"Angiopoietin-3 inhibits pulmonary metastasis by inhibiting tumor angiogenesis","volume":"64","author":"Xu","year":"2004","journal-title":"Cancer Res."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"15732","DOI":"10.1074\/jbc.274.22.15732","article-title":"Hypoxia and vascular endothelial growth factor selectively up-regulate angiopoietin-2 in bovine microvascular endothelial cells","volume":"274","author":"Oh","year":"1999","journal-title":"J. Biol. Chem."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1006\/bbrc.2000.2296","article-title":"Tumor necrosis factor-alpha upregulates angiopoietin- 2 in human umbilical vein endothelial cells","volume":"269","author":"Kim","year":"2000","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2949","DOI":"10.1016\/j.ajpath.2015.07.010","article-title":"Synergistic actions of blocking angiopoietin-2 and tumor necrosis factor-alpha in suppressing remodeling of blood vessels and lymphatics in airway inflammation","volume":"185","author":"Le","year":"2015","journal-title":"Am. J. Pathol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1126\/science.277.5322.55","article-title":"Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis","volume":"277","author":"Maisonpierre","year":"1997","journal-title":"Science"},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Parikh, S.M., Mammoto, T., Schultz, A., Yuan, H.T., Christiani, D., Karumanchi, S.A., and Sukhatme, V.P. (2006). Excess circulating angiopoietin-2 may contribute to pulmonary vascular leak in sepsis in humans. PLoS Med., 3.","DOI":"10.1371\/journal.pmed.0030046"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"3436","DOI":"10.1172\/JCI66549","article-title":"Angiopoietin 2 mediates microvascular and hemodynamic alterations in sepsis","volume":"123","author":"Ziegler","year":"2013","journal-title":"J. Clin. Investig."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"3495","DOI":"10.1172\/JCI84923","article-title":"Tie1 controls angiopoietin function in vascular remodeling and inflammation","volume":"126","author":"Korhonen","year":"2016","journal-title":"J. Clin. Investig."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1073\/pnas.1519467113","article-title":"Gene control of tyrosine kinase TIE2 and vascular manifestations of infections","volume":"113","author":"Ghosh","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1016\/j.celrep.2015.08.024","article-title":"The Orphan Receptor Tie1 Controls Angiogenesis and Vascular Remodeling by Differentially Regulating Tie2 in Tip and Stalk Cells","volume":"12","author":"Savant","year":"2015","journal-title":"Cell Rep."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1172\/JCI68897","article-title":"Tie1 deletion inhibits tumor growth and improves angiopoietin antagonist therapy","volume":"124","author":"Korhonen","year":"2014","journal-title":"J. Clin. Investig."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1172\/JCI94674","article-title":"Endothelial Tie1-mediated angiogenesis and vascular abnormalization promote tumor progression and metastasis","volume":"128","author":"Roth","year":"2018","journal-title":"J. Clin. Investig."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"e11164","DOI":"10.15252\/emmm.201911164","article-title":"Preclinical validation of a novel metastasis-inhibiting Tie1 function-blocking antibody","volume":"12","author":"Singhal","year":"2020","journal-title":"EMBO Mol. Med."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1084\/jem.20150718","article-title":"Interfering with VE-PTP stabilizes endothelial junctions in vivo via Tie-2 in the absence of VE-cadherin","volume":"212","author":"Frye","year":"2015","journal-title":"J. Exp. Med."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"5962","DOI":"10.1038\/ncomms6962","article-title":"Endothelial destabilization by angiopoietin-2 via integrin beta1 activation","volume":"6","author":"Hakanpaa","year":"2015","journal-title":"Nat. Commun."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"2980","DOI":"10.1038\/s41467-020-16795-4","article-title":"Angiopoietin-2-integrin alpha5beta1 signaling enhances vascular fatty acid transport and prevents ectopic lipid-induced insulin resistance","volume":"11","author":"Bae","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"4476","DOI":"10.1073\/pnas.1525360113","article-title":"Ang-2\/VEGF bispecific antibody reprograms macrophages and resident microglia to anti-tumor phenotype and prolongs glioblastoma survival","volume":"113","author":"Kloepper","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1620\/tjem.213.33","article-title":"Expression of angiopoietin-2 is correlated with vascularization and tumor size in human colorectal adenocarcinoma","volume":"213","author":"Wang","year":"2007","journal-title":"Tohoku J. Exp. Med."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1158\/0008-5472.CAN-09-1977","article-title":"Complementary actions of inhibitors of angiopoietin-2 and VEGF on tumor angiogenesis and growth","volume":"70","author":"Hashizume","year":"2010","journal-title":"Cancer Res."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1126\/science.284.5422.1994","article-title":"Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF","volume":"284","author":"Holash","year":"1999","journal-title":"Science"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"3835","DOI":"10.1158\/0008-5472.CAN-06-4056","article-title":"Systemic overexpression of angiopoietin-2 promotes tumor microvessel regression and inhibits angiogenesis and tumor growth","volume":"67","author":"Cao","year":"2007","journal-title":"Cancer Res."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/nature17038","article-title":"Metastatic colonization by circulating tumour cells","volume":"529","author":"Massague","year":"2016","journal-title":"Nature"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1038\/nature06385","article-title":"Isolation of rare circulating tumour cells in cancer patients by microchip technology","volume":"450","author":"Nagrath","year":"2007","journal-title":"Nature"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1158\/2159-8290.CD-15-0012","article-title":"Real-Time Imaging Reveals Local, Transient Vascular Permeability, and Tumor Cell Intravasation Stimulated by TIE2(hi) Macrophage-Derived VEGFA","volume":"5","author":"Harney","year":"2015","journal-title":"Cancer Discov."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/S0002-9440(10)64920-6","article-title":"Abnormalities in pericytes on blood vessels and endothelial sprouts in tumors","volume":"160","author":"Morikawa","year":"2002","journal-title":"Am. J. Pathol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1016\/S0002-9440(10)63540-7","article-title":"Abnormalities of basement membrane on blood vessels and endothelial sprouts in tumors","volume":"163","author":"Baluk","year":"2003","journal-title":"Am. J. Pathol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.3390\/cancers6031670","article-title":"Tumor-associated macrophages as major players in the tumor microenvironment","volume":"6","author":"Chanmee","year":"2014","journal-title":"Cancers"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.celrep.2013.07.021","article-title":"The calcineurin-NFAT-angiopoietin-2 signaling axis in lung endothelium is critical for the establishment of lung metastases","volume":"4","author":"Minami","year":"2013","journal-title":"Cell Rep."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"7529","DOI":"10.1158\/0008-5472.CAN-08-4382","article-title":"Pulmonary vascular destabilization in the premetastatic phase facilitates lung metastasis","volume":"69","author":"Huang","year":"2009","journal-title":"Cancer Res."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/j.ccell.2014.11.005","article-title":"Postsurgical adjuvant tumor therapy by combining anti-angiopoietin-2 and metronomic chemotherapy limits metastatic growth","volume":"26","author":"Srivastava","year":"2014","journal-title":"Cancer Cell"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/ijc.27677","article-title":"G-CSF rescues tumor growth and neo-angiogenesis during liver metastasis under host angiopoietin-2 deficiency","volume":"132","author":"Im","year":"2013","journal-title":"Int. J. Cancer"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1200\/JCO.2010.30.0855","article-title":"Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: Results of NSABP protocol C-08","volume":"29","author":"Allegra","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1016\/S1470-2045(12)70509-0","article-title":"Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): A phase 3 randomised controlled trial","volume":"13","author":"Schmoll","year":"2012","journal-title":"Lancet Oncol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/nm988","article-title":"Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer","volume":"10","author":"Willett","year":"2004","journal-title":"Nat. Med."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1007\/s10456-014-9420-y","article-title":"Anti-angiogenic therapy for cancer: Current progress, unresolved questions and future directions","volume":"17","author":"Vasudev","year":"2014","journal-title":"Angiogenesis"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"3347","DOI":"10.1158\/0008-5472.CAN-12-3518","article-title":"Bevacizumab- induced normalization of blood vessels in tumors hampers antibody uptake","volume":"73","author":"Arjaans","year":"2013","journal-title":"Cancer Res."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"7144","DOI":"10.1158\/0008-5472.CAN-13-1989","article-title":"Benefits of vascular normalization are dose and time dependent--letter","volume":"73","author":"Huang","year":"2013","journal-title":"Cancer Res."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"17561","DOI":"10.1073\/pnas.1215397109","article-title":"Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy","volume":"109","author":"Huang","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1177\/1947601909356574","article-title":"Mechanisms of resistance to anti-angiogenic therapy and development of third-generation anti-angiogenic drug candidates","volume":"1","author":"Loges","year":"2010","journal-title":"Genes Cancer"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/j.celrep.2014.06.059","article-title":"Role of angiopoietin-2 in adaptive tumor resistance to VEGF signaling blockade","volume":"8","author":"Rigamonti","year":"2014","journal-title":"Cell Rep."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1158\/0008-5472.CAN-12-2064","article-title":"Angiopoietin-2 functions as a Tie2 agonist in tumor models, where it limits the effects of VEGF inhibition","volume":"73","author":"Daly","year":"2013","journal-title":"Cancer Res."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.ccr.2010.07.001","article-title":"Double antiangiogenic protein, DAAP, targeting VEGF-A and angiopoietins in tumor angiogenesis, metastasis, and vascular leakage","volume":"18","author":"Koh","year":"2010","journal-title":"Cancer Cell"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"4470","DOI":"10.1073\/pnas.1525349113","article-title":"Dual inhibition of Ang-2 and VEGF receptors normalizes tumor vasculature and prolongs survival in glioblastoma by altering macrophages","volume":"113","author":"Peterson","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"6988","DOI":"10.1158\/0008-5472.CAN-16-0888","article-title":"Efficacy of Cotargeting Angiopoietin-2 and the VEGF Pathway in the Adjuvant Postsurgical Setting for Early Breast, Colorectal, and Renal Cancers","volume":"76","author":"Wu","year":"2016","journal-title":"Cancer Res."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"e451","DOI":"10.1634\/theoncologist.2019-0291","article-title":"The McCAVE Trial: Vanucizumab plus mFOLFOX-6 Versus Bevacizumab plus mFOLFOX-6 in Patients with Previously Untreated Metastatic Colorectal Carcinoma (mCRC)","volume":"25","author":"Bendell","year":"2020","journal-title":"Oncologist"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/j.ophtha.2019.03.023","article-title":"Simultaneous Inhibition of Angiopoietin-2 and Vascular Endothelial Growth Factor-A with Faricimab in Diabetic Macular Edema: BOULEVARD Phase 2 Randomized Trial","volume":"126","author":"Sahni","year":"2019","journal-title":"Ophthalmology"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/S1470-2045(14)70244-X","article-title":"Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): A randomised, multicentre, double-blind, placebo-controlled phase 3 trial","volume":"15","author":"Monk","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/bjc.2012.594","article-title":"A randomised, double-blind, placebo-controlled phase 2 study of trebananib (AMG 386) in combination with FOLFIRI in patients with previously treated metastatic colorectal carcinoma","volume":"108","author":"Peeters","year":"2013","journal-title":"Br. J. Cancer"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"6152","DOI":"10.1002\/cncr.27632","article-title":"AMG 386 in combination with sorafenib in patients with metastatic clear cell carcinoma of the kidney: A randomized, double-blind, placebo-controlled, phase 2 study","volume":"118","author":"Rini","year":"2012","journal-title":"Cancer"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1093\/rheumatology\/kes093","article-title":"Interleukin-6 promotes destabilized angiogenesis by modulating angiopoietin expression in rheumatoid arthritis","volume":"51","author":"Kayakabe","year":"2012","journal-title":"Rheumatology"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"469","DOI":"10.4049\/jimmunol.169.1.469","article-title":"Proinflammatory cytokine IL-1 beta promotes tumor growth of Lewis lung carcinoma by induction of angiogenic factors: In vivo analysis of tumor-stromal interaction","volume":"169","author":"Saijo","year":"2002","journal-title":"J. Immunol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"3551","DOI":"10.1242\/jcs.03077","article-title":"Activation of Tie2 by angiopoietin-1 and angiopoietin-2 results in their release and receptor internalization","volume":"119","author":"Bogdanovic","year":"2006","journal-title":"J. Cell Sci."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","article-title":"Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma","volume":"377","author":"Wolchok","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1126\/science.271.5256.1734","article-title":"Enhancement of antitumor immunity by CTLA-4 blockade","volume":"271","author":"Leach","year":"1996","journal-title":"Science"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"12293","DOI":"10.1073\/pnas.192461099","article-title":"Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade","volume":"99","author":"Iwai","year":"2002","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1200\/JCO.2014.56.2736","article-title":"Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma","volume":"33","author":"Schadendorf","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","article-title":"Safety and activity of anti-PD-L1 antibody in patients with advanced cancer","volume":"366","author":"Brahmer","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1056\/NEJMoa1414428","article-title":"Nivolumab and ipilimumab versus ipilimumab in untreated melanoma","volume":"372","author":"Postow","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/nature21349","article-title":"Elements of cancer immunity and the cancer-immune set point","volume":"541","author":"Chen","year":"2017","journal-title":"Nature"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/nature25501","article-title":"TGFbeta attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells","volume":"554","author":"Mariathasan","year":"2018","journal-title":"Nature"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"5449","DOI":"10.1158\/1078-0432.CCR-18-1543","article-title":"The Intersection between Tumor Angiogenesis and Immune Suppression","volume":"25","author":"Rahma","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.4049\/jimmunol.160.3.1224","article-title":"Vascular endothelial growth factor affects dendritic cell maturation through the inhibition of nuclear factor-kappa B activation in hemopoietic progenitor cells","volume":"160","author":"Oyama","year":"1998","journal-title":"J. Immunol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"4878","DOI":"10.1182\/blood-2002-07-1956","article-title":"VEGF inhibits T-cell development and may contribute to tumor-induced immune suppression","volume":"101","author":"Ohm","year":"2003","journal-title":"Blood"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1038\/nrclinonc.2018.9","article-title":"Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa","volume":"15","author":"Khan","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1038\/nature21724","article-title":"Mutual regulation of tumour vessel normalization and immunostimulatory reprogramming","volume":"544","author":"Tian","year":"2017","journal-title":"Nature"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"6171","DOI":"10.1158\/0008-5472.CAN-10-0153","article-title":"Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer","volume":"70","author":"Shrimali","year":"2010","journal-title":"Cancer Res."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"eaak9679","DOI":"10.1126\/scitranslmed.aak9679","article-title":"Combined antiangiogenic and anti-PD-L1 therapy stimulates tumor immunity through HEV formation","volume":"9","author":"Allen","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"eaak9670","DOI":"10.1126\/scitranslmed.aak9670","article-title":"Dual angiopoietin-2 and VEGFA inhibition elicits antitumor immunity that is enhanced by PD-1 checkpoint blockade","volume":"9","author":"Schmittnaegel","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1158\/2326-6066.CIR-14-0053","article-title":"Bevacizumab plus ipilimumab in patients with metastatic melanoma","volume":"2","author":"Hodi","year":"2014","journal-title":"Cancer Immunol. Res."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","article-title":"Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma","volume":"373","author":"Motzer","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1038\/nrclinonc.2017.101","article-title":"The immune contexture in cancer prognosis and treatment","volume":"14","author":"Fridman","year":"2017","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"277ra30","DOI":"10.1126\/scitranslmed.aaa1260","article-title":"Immunological mechanisms of the antitumor effects of supplemental oxygenation","volume":"7","author":"Hatfield","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1084\/jem.20140559","article-title":"VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors","volume":"212","author":"Voron","year":"2015","journal-title":"J. Exp. Med."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"5270","DOI":"10.1158\/0008-5472.CAN-10-0012","article-title":"Angiopoietin-2 regulates gene expression in TIE2-expressing monocytes and augments their inherent proangiogenic functions","volume":"70","author":"Coffelt","year":"2010","journal-title":"Cancer Res."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"5050","DOI":"10.1182\/blood-2011-03-343293","article-title":"Angiopoietin-2 promotes myeloid cell infiltration in a beta(2)-integrin-dependent manner","volume":"118","author":"Scholz","year":"2011","journal-title":"Blood"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"4183","DOI":"10.4049\/jimmunol.1002802","article-title":"Angiopoietin 2 stimulates TIE2-expressing monocytes to suppress T cell activation and to promote regulatory T cell expansion","volume":"186","author":"Coffelt","year":"2011","journal-title":"J. Immunol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.smim.2014.01.008","article-title":"The two faces of IL-6 in the tumor microenvironment","volume":"26","author":"Fisher","year":"2014","journal-title":"Semin. Immunol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.immuni.2010.05.010","article-title":"Tumor-induced tolerance and immune suppression depend on the C\/EBPbeta transcription factor","volume":"32","author":"Marigo","year":"2010","journal-title":"Immunity"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/j.trecan.2017.10.002","article-title":"Reprogramming Tumor Blood Vessels for Enhancing Immunotherapy","volume":"3","author":"Schmittnaegel","year":"2017","journal-title":"Trends Cancer"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1172\/JCI129558","article-title":"Antiangiogenic immunotherapy suppresses desmoplastic and chemoresistant intestinal tumors in mice","volume":"130","author":"Ragusa","year":"2020","journal-title":"J. Clin. Investig."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1073\/pnas.1902145116","article-title":"Optimized antiangiogenic reprogramming of the tumor microenvironment potentiates CD40 immunotherapy","volume":"117","author":"Kashyap","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/s41568-019-0116-x","article-title":"The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy","volume":"19","author":"Havel","year":"2019","journal-title":"Nat. Rev. Cancer"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"e542","DOI":"10.1016\/S1470-2045(16)30406-5","article-title":"Predictive biomarkers for checkpoint inhibitor-based immunotherapy","volume":"17","author":"Gibney","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/nrc.2016.36","article-title":"Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy","volume":"16","author":"Topalian","year":"2016","journal-title":"Nat. Rev. Cancer"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1126\/science.aan6733","article-title":"Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade","volume":"357","author":"Le","year":"2017","journal-title":"Science"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1126\/science.aaa1348","article-title":"Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer","volume":"348","author":"Rizvi","year":"2015","journal-title":"Science"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1126\/science.aad0095","article-title":"Genomic correlates of response to CTLA-4 blockade in metastatic melanoma","volume":"350","author":"Miao","year":"2015","journal-title":"Science"},{"key":"ref_129","doi-asserted-by":"crossref","unstructured":"Cristescu, R., Mogg, R., Ayers, M., Albright, A., Murphy, E., Yearley, J., Sher, X., Liu, X.Q., Lu, H., and Nebozhyn, M. (2018). Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy. Science, 362.","DOI":"10.1126\/science.aar3593"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/nature13954","article-title":"PD-1 blockade induces responses by inhibiting adaptive immune resistance","volume":"515","author":"Tumeh","year":"2014","journal-title":"Nature"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/s41591-018-0053-3","article-title":"Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma","volume":"24","author":"McDermott","year":"2018","journal-title":"Nat. Med."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.3389\/fimmu.2018.01474","article-title":"Biomarkers for Clinical Benefit of Immune Checkpoint Inhibitor Treatment-A Review from the Melanoma Perspective and Beyond","volume":"9","author":"Hassel","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"376","DOI":"10.21037\/atm.2017.06.48","article-title":"Beyond PD-L1 testing-emerging biomarkers for immunotherapy in non-small cell lung cancer","volume":"5","author":"Voong","year":"2017","journal-title":"Ann. Transl. Med."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1038\/s41586-018-0392-8","article-title":"Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response","volume":"560","author":"Chen","year":"2018","journal-title":"Nature"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.it.2015.02.005","article-title":"Intertwined regulation of angiogenesis and immunity by myeloid cells","volume":"36","author":"Rivera","year":"2015","journal-title":"Trends Immunol."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1158\/2326-6066.CIR-13-0163","article-title":"Pretreatment serum VEGF is associated with clinical response and overall survival in advanced melanoma patients treated with ipilimumab","volume":"2","author":"Yuan","year":"2014","journal-title":"Cancer Immunol. Res."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"eaal4712","DOI":"10.1126\/scitranslmed.aal4712","article-title":"Tumor lymphangiogenesis promotes T cell infiltration and potentiates immunotherapy in melanoma","volume":"9","author":"Fankhauser","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"ref_139","first-page":"2145","article-title":"Angiopoietin-2 is related to tumor angiogenesis in gastric carcinoma: Possible in vivo regulation via induction of proteases","volume":"61","author":"Etoh","year":"2001","journal-title":"Cancer Res."},{"key":"ref_140","first-page":"539","article-title":"Clinical significance of angiopoietin-2 expression at the deepest invasive tumor site of advanced colorectal carcinoma","volume":"24","author":"Ochiumi","year":"2004","journal-title":"Int. J. Oncol."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1002\/ijc.10851","article-title":"Angiopoietin-2 expression in breast cancer correlates with lymph node invasion and short survival","volume":"103","author":"Sfiligoi","year":"2003","journal-title":"Int. J. Cancer"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1158\/1078-0432.CCR-08-1615","article-title":"Angiopoietin-2 levels are associated with disease progression in metastatic malignant melanoma","volume":"15","author":"Helfrich","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1038\/sj.bjc.6605925","article-title":"Identification of serum angiopoietin-2 as a biomarker for clinical outcome of colorectal cancer patients treated with bevacizumab-containing therapy","volume":"103","author":"Goede","year":"2010","journal-title":"Br. J. Cancer"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1158\/2326-6066.CIR-16-0206","article-title":"Angiopoietin-2 as a Biomarker and Target for Immune Checkpoint Therapy","volume":"5","author":"Wu","year":"2017","journal-title":"Cancer Immunol. Res."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/21\/22\/8689\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T10:33:39Z","timestamp":1760178819000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/21\/22\/8689"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,18]]},"references-count":144,"journal-issue":{"issue":"22","published-online":{"date-parts":[[2020,11]]}},"alternative-id":["ijms21228689"],"URL":"https:\/\/doi.org\/10.3390\/ijms21228689","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,18]]}}}